文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

用于胶质母细胞瘤治疗的纳米增敏剂:最新进展与未来展望。

Nanoradiosensitizers in glioblastoma treatment: recent advances and future perspectives.

机构信息

Department of Neurosurgery, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, China.

Department of Neuro-Psychiatric Institute, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, China.

出版信息

Nanomedicine (Lond). 2024;19(26):2229-2249. doi: 10.1080/17435889.2024.2395238. Epub 2024 Sep 23.


DOI:10.1080/17435889.2024.2395238
PMID:39311492
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11487349/
Abstract

Glioblastoma (GBM), a highly invasive type of brain tumor located within the central nervous system, manifests a median survival time of merely 14.6 months. Radiotherapy kills tumor cells through focused high-energy radiation and has become a crucial treatment strategy for GBM, especially in cases where surgical resection is not viable. However, the presence of radioresistant tumor cells limits its clinical effectiveness. Radioresistance is a key factor of treatment failure, prompting the development of various therapeutic strategies to overcome this challenge. With the rapid development of nanomedicine, nanoradiosensitizers provide a novel approach to enhancing the effectiveness of radiotherapy. In this review, we discuss the reasons behind GBM radio-resistance and the mechanisms of radiotherapy sensitization. Then we summarize the primary types of nanoradiosensitizers and recent progress in their application for the radiosensitization of GBM. Finally, we elucidate the factors influencing their practical implementation, along with the challenges and promising prospects associated with multifunctional nanoradiosensitizers.

摘要

胶质母细胞瘤(GBM)是一种位于中枢神经系统内的高度侵袭性脑肿瘤,中位生存时间仅为 14.6 个月。放疗通过聚焦高能射线杀死肿瘤细胞,已成为 GBM 的重要治疗策略,特别是在手术切除不可行的情况下。然而,存在放射抵抗的肿瘤细胞限制了其临床效果。放射抵抗是治疗失败的关键因素,促使人们开发各种治疗策略来克服这一挑战。随着纳米医学的快速发展,纳米放射增敏剂为提高放疗效果提供了一种新方法。在这篇综述中,我们讨论了 GBM 放射抵抗的原因和放射增敏的机制。然后总结了主要类型的纳米放射增敏剂及其在 GBM 放射增敏中的应用的最新进展。最后,我们阐明了影响其实际应用的因素,以及多功能纳米放射增敏剂所面临的挑战和有前景的方面。

相似文献

[1]
Nanoradiosensitizers in glioblastoma treatment: recent advances and future perspectives.

Nanomedicine (Lond). 2024

[2]
GRPR-targeted gold nanoparticles as selective radiotherapy enhancers in glioblastoma.

Phys Med Biol. 2025-6-20

[3]
Stemness, invasion, and immunosuppression modulation in recurrent glioblastoma using nanotherapy.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024

[4]
Ultrasmall nanoparticles for co-delivery of antisense oligonucleotides targeting miR-21 and miR-210 to treat glioblastoma.

J Nanobiotechnology. 2025-7-2

[5]
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.

Cochrane Database Syst Rev. 2021-5-4

[6]
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.

Cochrane Database Syst Rev. 2020-3-23

[7]
Lactate-coated polyurea-siRNA dendriplex: a gene therapy-directed and metabolism-based strategy to impair glioblastoma (GBM).

Cancer Gene Ther. 2025-4-27

[8]
Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors.

J Pharmacol Exp Ther. 2024-10-18

[9]
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.

Int J Mol Sci. 2023-10-10

[10]
C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET).

BMC Cancer. 2024-6-15

本文引用的文献

[1]
Bioinspired Lipoproteins of Furoxans-Gemcitabine Preferentially Targets Glioblastoma and Overcomes Radiotherapy Resistance.

Adv Sci (Weinh). 2024-2

[2]
Bioengineered Bacteriophage-Like Nanoparticles as RNAi Therapeutics to Enhance Radiotherapy against Glioblastomas.

ACS Nano. 2023-6-13

[3]
Gold nanoparticles enhances radiosensitivity in glioma cells by inhibiting TRAF6/NF-κB induced CCL2 expression.

Heliyon. 2023-3-9

[4]
STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma.

Nat Commun. 2023-3-23

[5]
Magnetite nanoparticles as a kinetically favorable source of iron to enhance GBM response to chemoradiosensitization with pharmacological ascorbate.

Redox Biol. 2023-6

[6]
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.

JAMA. 2023-2-21

[7]
Radiation-Triggered Selenium-Engineered Mesoporous Silica Nanocapsules for RNAi Therapy in Radiotherapy-Resistant Glioblastoma.

ACS Nano. 2023-2-28

[8]
Radiosensitization with Gadolinium Chelate-Coated Gold Nanoparticles Prevents Aggressiveness and Invasiveness in Glioblastoma.

Int J Nanomedicine. 2023

[9]
Stem cell-nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy.

Nat Commun. 2023-1-18

[10]
EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.

Neuro Oncol. 2023-5-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索